“Great personal patient attention. Very organized. They handled everything for my cataract surgery and follow-up appointments were informative. Great staff.”
Plaquenil Eye Screening: What the OCT and Visual Field Test Are Looking For
How to Prepare for Your Screening Visit
Plaquenil screening does not require much preparation on your part, but arriving with the right information helps your retina specialist interpret your results accurately and keep your prescribing physician in the loop. A little planning before your visit makes the whole process faster and more useful.
Three pieces of information are most useful: your current daily dose, the date you started the medication, and your most recent kidney function result if you have one. Your eye care team and your prescribing physician (your rheumatologist, dermatologist, or other specialist) should communicate directly, and you are often the fastest link between them.
Bring your glasses or contact lenses, and pack a pair of sunglasses in case dilating drops are used. Dilation temporarily makes daylight feel harsh and blurs near vision for a few hours, so if you are unsure whether drops will be needed, arrange a ride just in case.
You do not need to stop taking your medication before screening, and you do not need to fast. The tests measure changes that accumulate over years, so an ordinary day is exactly what your doctor wants to see.
When you book the appointment, use the words 'hydroxychloroquine screening' so the office schedules the correct tests, specifically the OCT scan and the visual field test, rather than a routine glasses check or a brief exam.
What Happens During Your Screening
A Plaquenil screening visit typically involves two primary tests and sometimes a third. None of them touch your eye, and none use radiation. Knowing what to expect from each one makes the visit easier and helps you give your best effort on the attention-based field test.
OCT stands for optical coherence tomography. It is a non-invasive imaging test that uses light waves to produce detailed cross-section pictures of each layer of your retina, similar to an ultrasound but using light instead of sound. Nothing contacts your eye during the scan.
You rest your chin and forehead on a support to hold your head still, focus on a small target inside the machine, and hold as steady as you can while it scans. The process takes roughly five to ten minutes and is quiet and painless. The most common complaint is that staying still feels awkward; the hardest part for most people is simply not blinking too much.
The visual field test measures what your retina can detect across a wide area, rather than what it looks like on a scan. You look into a bowl-shaped device called a perimeter, focus on a fixed central target, and press a button whenever you see a small dim light appear somewhere in your peripheral view. The machine records which lights you did not respond to.
You may blink normally during the test, and you may pause if you need a break. Most people find the test tiring rather than uncomfortable, and taking a pause when your attention drifts actually improves the reliability of the results. Reliability matters more than speed here.
Many practices now add a wide-field fundus autofluorescence photograph as part of the standard Plaquenil screening visit. This photo captures how the retinal pigment glows under a specific wavelength of light, and it can reveal early damage as a bright area before thinning even appears on the OCT scan.
The photo takes only seconds and is not a sign that anything is wrong. Current guidelines name the OCT scan together with wide-pattern autofluorescence as the two primary screening tools, ideally covering a wide enough area to detect damage that sits beyond the small central zone.
Two people on the same medication can be handed different visual field patterns, and that is intentional. The area of the retina most at risk varies based on ancestry, risk factors, and prior results.
A 10-2 field pattern tests a small ring close to the center of vision and is the standard starting point for most patients. A 24-2, 30-2, or 24-2C pattern covers a wider zone and is recommended when the pericentral area (further out, near the vessel arcades) is more likely to be involved. Patients of Asian descent are more likely to develop the pericentral pattern, so a wider field test may be used from the start. Your retina specialist selects the pattern based on your individual profile, not a one-size-fits-all default.
What the Tests Are Actually Looking For
Each test examines the retina from a different angle, and together they can detect damage that neither test would reliably find alone. Understanding what your doctor is reading on the images and printouts helps the results feel less abstract when you get them.
On an OCT scan, healthy photoreceptors appear as bright, continuous lines in the outer retina. The most important of these for hydroxychloroquine screening is called the ellipsoid zone, the band where light-sensing cells pack the machinery they use to process light.
The earliest sign of toxicity is focal granular fragmentation, thinning, or loss of this ellipsoid zone in the parafoveal area. Disruption of the external limiting membrane, a nearby marker layer, signals a more advanced stage. Your doctor compares this year's images against your baseline scan, which is why the first visit matters even though it almost always looks normal.
This is the most common pattern of hydroxychloroquine retinopathy. Outer retinal tissue thins in a ring around the fovea while the tissue directly beneath the fovea remains intact. On the OCT scan, the preserved central area creates a distinctive appearance sometimes called the 'flying saucer sign,' where the ellipsoid zone is lost on both sides of the fovea but still visible underneath it.
Because this damaged ring sits just off the very center of your vision, you can read, recognize faces, and function normally without noticing anything unusual. That invisible quality is exactly what the tests are designed to overcome.
Some patients develop damage in a wider ring, well beyond the small central zone that a 10-2 visual field or a standard OCT scan would cover. This pattern shows as thinning and loss of outer retinal layers further from the fovea, and it is confirmed with wide-pattern autofluorescence.
The pericentral pattern is more common among patients of Asian descent, though it can occur in anyone. Because a standard 10-2 field test alone may not detect it, current guidelines recommend wide imaging for all patients and a broader field pattern when pericentral damage is a concern. Your own pattern is never assumed in advance.
The visual field test is hunting for a scotoma, a patch where the retina is less sensitive than it should be. In early hydroxychloroquine retinopathy, the typical finding is a paracentral scotoma in the zone roughly two to six degrees out from the center of fixation in most patients.
You would not normally notice a scotoma this small in daily life, because your other eye and your constant small eye movements fill in the gap automatically. On the field printout, early defects typically appear in the upper inner portion of the field, which corresponds to the lower outer retina where damage tends to begin. If your printout shows a cluster of abnormal points in that area, your doctor will look at the matching region on the OCT scan.
Understanding Your Results
Getting your results explained clearly, including what they rule out and what they do not, helps you make good decisions about follow-up and about the conversations you have with your prescribing physician. Results exist on a spectrum, and a single abnormal test rarely tells the whole story on its own.
A normal screening result means no damage was detectable with today's tests. That is genuinely reassuring. It does not mean the risk disappears going forward, because it continues to build with years of use.
Normal results so far are good news about the years behind you. They are also an argument for keeping next year's appointment, not for skipping it.
If one test shows a borderline finding, expect a repeat rather than a verdict. Visual field testing depends on attention and stamina, and a single unusual result is common and often does not hold up on repeat. Your doctor may re-run the field test, look more closely at the corresponding area on the OCT, or use an additional test called multifocal electroretinography, which measures the electrical response of the retina point by point, to corroborate or rule out the finding.
Medical guidance specifically warns against stopping hydroxychloroquine based on borderline findings. It is a valuable drug for the conditions it treats, and a suspicious screening result typically leads to closer monitoring rather than an immediate change in your medication.
A confirmed finding does not mean your vision will deteriorate rapidly, and it does not mean the decision about your medication is made for you alone. The appropriate next step is a shared conversation involving you, your prescribing physician, and your eye care provider, weighing the severity of the retinal finding against the importance of the medication for your underlying condition.
Stage matters enormously here. Damage caught at a mild stage, while a key marker layer called the external limiting membrane is still intact, tends to show only slight progression for about a year after stopping the drug and then stabilizes, with a low risk of central vision loss. When damage is more advanced and involves deeper retinal layers, progression toward central vision loss may continue even after the drug is stopped. That difference in outcome is the entire reason the yearly appointment is worth protecting.
When to Call Between Screenings
Annual screening is built for the period when damage is too subtle to notice. If you actually notice a change in your vision between visits, that is worth a prompt call rather than a wait until next year's appointment. Catching a problem earlier is always better than waiting for a scheduled slot.
Any new or worsening visual symptom is worth mentioning to your eye care team, even if it turns out to have a routine explanation such as a change in glasses or an early cataract.
- Words or letters dropping out mid-line while reading
- A blurry or blank patch near (but not exactly at) the center of your vision
- Colors that look washed out or duller than they used to
- Needing noticeably more light to read than you did a year ago
- Difficulty adjusting when moving from bright light into a dim room
Call your eye care provider, describe what changed and when you noticed it, and ask whether your screening should be moved up.
For most people on this medication, routine follow-up means one screening visit per year once annual checks have begun. A baseline visit is recommended shortly after starting the drug. Annual screening may be deferred through the first five years for people with no significant risk factors, but it starts right away for anyone who does have them.
Booking the same month each year and tying it to another annual task, such as a physical or a dental visit, makes it easier to keep the appointment from quietly slipping off the calendar.
Frequently Asked Questions
These answers address the practical questions that come up most often and are not fully covered by the sections above.
The scan is painless and nothing contacts your eye at any point. The main physical challenge is holding your head still and minimizing blinking for a few minutes. Whether you can drive afterward depends on whether dilating drops are used, and that varies by practice and by what your doctor wants to see. Drops blur near vision and make bright light uncomfortable for several hours. If you are unsure whether you will be dilated, arrange a ride and bring sunglasses. If no drops are used, driving is generally fine.
No, and a long run of normal results is not a reason to stop. Risk builds continuously with duration rather than leveling off after a certain number of years, so the tenth or twelfth year of use is not a safe stopping point for screening. The option to defer annual checks applies only to the first five years, and only for patients with no significant risk factors. Your record of normal results is genuinely good news about the time behind you, and it is worth protecting that record by continuing to come in each year.
In most cases, it means the field test needs repeating before any conclusions are drawn. Field testing is sensitive to attention, fatigue, and how well you understood the instructions, and a single borderline result is common and frequently does not reproduce on a second run. Your doctor may repeat the field, look more carefully at the area of the scan that corresponds to the abnormal field points, or both. A single discordant result is not a basis for stopping your medication, and your care team will guide you through whatever follow-up is appropriate.
It can, and it is worth raising with your retina specialist directly if you have not already. Patients of Asian descent are more likely to develop the pericentral pattern of retinopathy, where damage sits further from the center of vision than a standard 10-2 visual field would detect. A wider field pattern (24-2, 30-2, or 24-2C) is recommended when pericentral involvement is a concern, and wide autofluorescence imaging is important for the same reason. Telling your eye care team your ancestry at the first visit ensures the right tests are ordered from the start.
There is currently no proven treatment that reverses or repairs hydroxychloroquine retinopathy. Stopping or reducing the drug is the only intervention with established evidence, and even that does not reverse damage that has already occurred. The distinction between mild, early-stage damage and more advanced damage matters a great deal for what happens after stopping, which is why the best available protection is finding any change at the earliest possible stage through consistent annual screening.
Bringing a short list of questions helps you leave the visit with a clear picture of where you stand. Consider asking how your daily dose compares to the recommended weight-based limit, whether your annual screening has officially begun or you are still within a deferral window, which visual field pattern was used and why, how this year's scan compares to your baseline, whether your kidney function or other medications place you in a higher risk group, and who will share today's results with your prescribing physician.
Schedule Your Plaquenil Screening at Atlantic Retina Center
Our fellowship-trained retina specialists have the imaging technology and clinical expertise to perform complete hydroxychloroquine screening, including OCT, wide-pattern autofluorescence, and visual field testing, in a single focused visit. We see patients across the Eastern Shore of Maryland and central and southern Delaware, with multiple office locations on the Delmarva peninsula for your convenience. If you are on hydroxychloroquine and have not had a baseline exam or your most recent annual check, we encourage you to reach out and schedule, because early detection is the most powerful tool available for protecting your vision.